Format

Send to

Choose Destination
Int J Med Sci. 2019 Jan 29;16(3):424-442. doi: 10.7150/ijms.30154. eCollection 2019.

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas.

Author information

1
Department of Minimally Invasive Intervention, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.
2
Health Management Center of Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.
3
China Central Laboratory of Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.

Abstract

T-cell lymphomas are a heterogeneous group of cancers with different pathogenesis and poor prognosis. Histone deacetylases (HDACs) are epigenetic modifiers that modulate many key biological processes. In recent years, HDACs have been fully investigated for their roles and potential as drug targets in T-cell lymphomas. In this review, we have deciphered the modes of action of HDACs, HDAC inhibitors as single agents, and HDACs guided combination therapies in T-cell lymphomas. The overview of HDACs on the stage of T-cell lymphomas, and HDACs guided therapies both as single agents and combination regimens endow great opportunities for the cure of T-cell lymphomas.

KEYWORDS:

Histone deacetylases (HDACs); T-cell lymphomas; combination therapy; cutaneous T-cell lymphoma; peripheral T-cell lymphoma

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center